Inadequate levels of essential nutrients in developed nations as a risk factor for disease: A review

Reviews on Environmental Health

Volumn 18, Issue 2, 2003, Pages 111-129

  Ely, John J T ^a,b  

^a UNIVERSITY OF WASHINGTON   (United States)

^b NONE   (New Zealand)

Author keywords

Ascorbic acid; Environmental health quality; Hyperglycemia; Refined diet; Ubiquinone; Vitamin C

Indexed keywords

ALPHA TOCOPHEROL; ASCORBIC ACID; DOCOSAHEXAENOIC ACID; ELASTIN; GLUCOSE; ICOSAPENTAENOIC ACID; LIPID; MERCURY; UBIQUINONE; XENOBIOTIC AGENT;

AGING; ALZHEIMER DISEASE; ATTITUDE; BIOENERGY; BIRTH DEFECT; CANCER; CARDIOVASCULAR DISEASE; DEVELOPING COUNTRY; DIET; ENVIRONMENTAL HEALTH; ESSENTIAL NUTRIENT; FOOD PROCESSING; GLUCOSE BLOOD LEVEL; HEALTH CARE COST; HEXOSE MONOPHOSPHATE SHUNT; HUMAN; HYPERGLYCEMIA; HYPOGLYCEMIA; INFECTION; INTOXICATION; LONGEVITY; MERCURIALISM; MORBIDITY; MORTALITY; NONHUMAN; NUTRIENT; NUTRITIONAL DEFICIENCY; PSYCHOSIS; REVIEW; RISK FACTOR; SOCIAL STATUS; STROKE; SUPPLEMENTATION; SURGERY; TUBERCULOSIS; UTERINE CERVIX DYSPLASIA; VIRUS INFECTION;

EID: 0141963315     PISSN: 00487554     EISSN: None     Source Type: Journal    
DOI: 10.1515/REVEH.2003.18.2.111     Document Type: Review

References (112)

1. The World Health Report 2000. WHO ISBN 924156198X June 2000. (www.who.int/whr/2001/archives/2000/en/index.htm)
2. Harman D. Prolongation of life: role of free radical reactions in aging. J Am Geriatr Soc 1969; 17: 721-735.
3. Harman D. The aging process. Proc Natl Acad Sci USA 1981; 78: 7124-7128.
4. Harman D. The biologic clock: the mitochondria? J Am Geriatr Soc 1972; 20: 145-147.
5. Reid R. Microbes and Men. London, UK: British Broadcasting Corporation, 1974.
6. Price WR. The present status of our knowledge of the relation of mouth infection to systemic disease. Dent Rev 1917 31: 271.
7. Pauling LJ. How to Live Longer and Feel Better New York, NY, USA: Avon Books, 1987.
8. Lewin S. Vitamin C: Its Molecular Biology and Medical Potential. New York, NY, USA: Academic Press, 1976.
9. Stone I. The Healing Factor. Vitamin C Against Disease. New York, NY, USA: Grosset & Dunlap, 1972, 152-171.
10. King CG. Ascorbic acid (Vitamin C) and scurvy. In: Williams RJ, Lansford EM, eds, Encyclopedia of Biochemistry. New York, NY, USA: Reinhold Pub; 1967; 95-99.
11. Cheraskin E, Ringsdorf MW Jr. How much refined carbohydrate should we eat? Am Lab 1974; 6: 31-35.
12. Shute WE, Dr Wilfred E. Shute's Complete Updated Vitamin E Book. New Canaan, Connecticut, USA: Keats, 1975.
13. Ochsner A, Kay JH, DeCamp PT, Gutton SB, Balla GA. Newer concepts of blood coagulation, with particular reference to postoperative thromboses. Ann Surg 1950; 131: 652-659.
14. Klenner FR. The treatment of poliomyelitis and other virus diseases with vitamin C. Southern Med Surg 1949; 111: 209-214.
15. Klenner FR. Observations on the dose and administration of ascorbic acid when employed beyond the range of a vitamin in human pathology. J Appl Nutr 1971; 23: 61-88.
16. Klenner FR. Significance of high daily intake of ascorbic acid in preventive medicine. J Prev Med 1974; Spring: 45-69. (also see www.orthomed.com)
17. Cathcart RF. Vitamin C, titrating to bowel tolerance, anascorbemia, and acute induced scurvy. Med Hypoth 1981; 7: 1359-1376. (also see www.orthomed.com)
18. Ernster L, Dallner G. Biochemical, physiological and medical aspects of ubiquinone function. Biochim Biophys Acta 1995; 1271: 195-204.
19. Cooper MR, McCall CE, DeChatelet LR. Stimulation of leukocyte hexose monophosphate shunt activity by ascorbic acid. Infect Immun 1971; 3: 851-853.
20. Grimble RF. Effect of antioxidative vitamins on immune function with clinical applications. Int J Vitam Nutr Res 1997; 67: 312-320.
21. Penn ND, Purkins L, Kelleher J, Heatley RV, Mascie-Taylor BH, Belfield PW. The effect of dietary supplementation with vitamins A, C and E on cell-mediated immune function in elderly longstay patients: a randomized controlled trial. Age Ageing 1991; 20: 169-174.
22. Jungeblut CW. Inactivation of poliomyelitis virus by crystalline vitamin C (ascorbic acid). J Exp Med 1935; 62: 317-321.
23. Ralli EP, Sherry S. Effect of insulin on plasma level and excretion of vitamin C. Proc Soc Exp Biol Med 1940; 43: 669-672.
24. Denson KW, Bowers EF. The determination of ascorbic acid in white blood cells. Clin Sci 1961; 21: 157-162.
25. Ely JTA. Warner GA, Read DH, Santisteban GA. Protein glycation: ascorbate antagonism [abstract] Bull Am Physical Soc 1988; 33: 296.
26. Krone CA, Ely JTA. Vitamin C and glycohemoglobin revisited. Clin Chem 2001; 47: 148.
27. Ely JTA. Hyperglycemia and major congenital anomalies. New Engl J Med 1981; 305: 833.
28. Hamel EE, Santisteban GA, Ely JTA, Read DH. Hyperglycemia and reproductive defects in non-diabetic gravidas: a mouse model test of a new theory. Life Sci 1986; 39: 1425-1428.
29. Santisteban GA, Ely JTA, Hamel EE, Read DH. Kozawa SM. Glycemic modulation of tumor tolerance in a mouse model of breast cancer. Biochem Biophys Res Commun 1985; 132: 1174-1179.
30. Ely JTA. Glycemic modulation of tumor tolerance. J Orthomolecular Med 1996; 11(1): 23-34.
31. Ely JTA, Krone CA. Glucose and cancer. New Zealand Med J 2002; 115(1159): U123.
32. Ely JTA. Unrecognized pandemic subclinical diabetes of the affluent nations: causes, cost and prevention. J Orthomolecular Med 1996; 11: 95-99.
33. Hems G. The contributions of diet and childbearing to breast cancer rates. Br J Cancer 1978; 37: 974-982.
34. Carroll KK. Dietary factors in hormone-dependent cancers. Curr Concepts Nutr 1977; 6: 25-40.
35. Augustin LS, Polesel J, Bosetti C, Kendall CW, La Vecchia C, Parpinel M, et al. Dietary glycemic index, glycemic load and ovarian cancer risk: a case-control study in Italy. Ann Oncol 2003; 14: 78-84.
36. Michaud DS, Liu S, Giovannucci E, Willett WC, Colditz GA, Fuchs CS. Dietary sugar, glycemic load, and pancreatic cancer risk in a prospective study. J Natl Cancer Inst 2002; 94: 1293-1300.
37. Nilsen TA, Vatten LJ. Prospective study of colorectal cancer risk and physical activity, diabetes, blood glucose and BMI: exploring the hyperinsulinaemia hypothesis. Br J Cancer 2001; 84: 417-422.
38. Schoen RE, Tangen CM, Kuller LH, Burke GL, Cushman M, Tracy RP, Dobs A, Savage PJ. Increased blood glucose and insulin, body size, and incident colorectal cancer. J Natl Cancer Inst 1999; 91: 1147-1154.
39. Chatterjee IB, Bannerjee A. Estimation of dehydroascorbic acid in blood of diabetic patients. Anal Biochem 1979; 98: 368-374.
40. nd ed. New York, NY, USA: Wiley, 1982.
41. Murata A, Morishige F, Yamaguchi H. Prolongation of survival times of terminal cancer patients by administration of large doses of ascorbate. Int J Vitamin Nutr Res Suppl 1982; 23: 103-113.
42. Riordan NH, Riordan HD, Meng X, Li Y, Jackson JA. Intravenous ascorbate as a tumor cytotoxic chemotherapeutic agent. Medical Hypothesis 1995; 44: 207-213.
43. Rivers JM. Safety of high-level vitamin C ingestion. Int J Vitamin Nutr Res Suppl 1989; 30: 95-102.
44. Koroljow S. Insulin coma therapy. Psychiatric Quarterly 1962; 36: 261-270.
45. Schroeder HA. The Trace Elements and Man. Old Greenwich, Connecticut: Devin-Adair, 1973; 64.
46. Ames BN. Micronutrients prevent cancer and delay aging. Toxicol Lett 1998; 102: 5-18.
47. Gey KF, Puska P, Jordan P, Moser U. Inverse correlation between plasma vitamin E and mortality from ischemic heart disease in cross-cultural epidemiology. Am J Clin Nutr 1991; 53: 326s-334s.
48. Ely JTA. Ascorbic acid and some other modern analogs of the germ theory. J Orthomolecular Med 1999; 14: 143-156.
49. Bliznakov EG, Wilkins DJ. Biochemical and clinical consequences of inhibiting Coenzyme Q10 biosynthesis by lipid-lowering HMG-CoA reductase inhibitors (statins): A critical overview. Adv Ther 1998; 15: 218-228.
50. Kalen A, Appelkvist E-L, Dallner G. Age related changes in the lipid composition of rat and human tissue. Lipids 1989; 24: 79-84.
51. Bliznakov EG. Aging, mitochondria, and coenzyme Q10: The neglected relationship. Biochimie 1999; 81: 1131-1132.
52. Linnane AW, Kovalenko S, Gingold EB. The universality of bioenergetic disease: age associated cellular bioenergetic degradation and amelioration therapy. Ann NY Acad Sci 1998; 854: 202-213.
53. Littarru GP. Energy and Defense. Roma, Italy: Casa Editrice Scientifica Intl, 1995.
54. Cerami A, Vlassare H, Brownlee M: Glucose and aging. Sci Amer 1987; 256: 90-96.
55. Horrobin DF, Bennett CN. Depression and bipolar disorder: relationships to impaired fatty acid and phospholipid metabolism and to diabetes, cardiovascular disease, immunological abnormalities, cancer, ageing and osteoporosis. Possible candidate genes. Prostaglandins, Leucotrienes and Essential Fatty Acids 1999; 40: 217-234.
56. Horrobin DF, Bennett CN. New gene targets related to schizophrenia and other psychiatric disorders: enzymes, binding proteins and transport proteins involved in phospholipid and fatty acid metabolism. Prostaglandins, Leucotrienes and Essential Fatty Acids 1999; 40: 141-167.
57. Horrobin DF. The membrane phospholipid hypothesis as a biochemical basis for the neurodevelopmental concept of schizophrenia. Schizophrenia Res 1998; 30: 193-208.
58. Baetgen D. Results of treating epidemic hepatitis with high dose ascorbic acid. Mediz Monatschr 1961; 15: 30-36.
59. Kirchmair VH, Kirsch B. Behandlung der hepatitis epidemica im kindesalter mit hohen dosen ascorbinsaure. Mediz Monatschr 1957; 11: 353-357.
60. Boissevain CH, Spillane JH. Effect of synthetic ascorbic acid on the growth of tuberculosis bacillus. Am Rev Tuberculosis 1937; 35: 661-662.
61. Sirsi M. Antimicrobial action of vitamin C on M. tuberculosis and some other pathogenic organisms. Indian J Med Sci (Bombay) 1952; 6: 252-255.
62. Ely JTA, Fudenberg HH, Bliznakov EG, Branch JD. Hemorrhagic stroke in human pretreated with coenzyme Q10: Exceptional recovery as seen in animal models. J Orthomolecular Med 1998; 13: 105-109.
63. Ely JTA, Krone CA. A brief update on ubiquinone (Coenzyme Q10). J Orthomolecular Med 2000; 15: 63-68.
64. Hiasa Y, Ishida T, Maeda T, Iwano K, Aihara T, Mori H. Effects of coenzyme Q10 on exercise tolerance in patients with stable angina pectoris. Biomed Clin Aspects Coenzyme Q 1984; 4: 291-301.
65. Niibori K, Wroblewski KP, Yokoyama H, Crestanello JA, Whitman GJ. Bioenergetic effect of liposomal coenzyme Q10 on myocardial ischemia reperfusion injury. Biofactors 1999; 9: 307.
66. Cousins L. Congenital anomalies among infants of diabetic mothers: etiology, prevention, prenatal diagnosis. Am J Obstet Gynecol 1983; 147: 333-338.
67. Sadler TW. Effects of maternal diabetes on early embryogenesis: II. Hyperglycemia-induced exencephaly. Teratology 1980; 21: 349-356.
68. Tallarigo L, Giampietro O, Penno G, Miccoli R, Gregori G, Navalesi R. Relation of glucose tolerance to complications of pregnancy in non-diabetic women. N Engl J Med 1986; 315: 989-992.
69. Gabbe SG. Gestational diabetes mellitus. N Engl J Med 1986; 315: 1025-1026.
70. Naeye RL, Sims EA, Welsh GW 3rd, Gray MJ. Newborn organ abnormalities. A guide to abnormal maternal glucose metabolism. Arch Pathol. 1966; 81: 552-557.
71. Stehbens JA, Baker GL, Kitchell M. Outcome at ages 1, 3, and 5 years of children born to diabetic women. Am J Obst Gyn 1977; 127: 408-413.
72. The President's Panel on Mental Retardation. A Proposed Program for National Action to Combat Mental Retardation. Washington, DC, USA: US Government Printing Office, 1962 [i.e., 1963]
73. Beischer NA, Wein P, Sheedy MT, Steffen B. Identification and treatment of women with hyperglycaemia diagnosed during pregnancy can significantly reduce perinatal mortality rates. Aust N Z J Obstet Gynaecol 1996; 36: 239-247.
74. Freund E. Zur diagnose des carcinoms. Wien Med 1885; B18: 267.
75. Marks PA, Bishop JS. Glucose metabolism in subjects with neoplastic disease response to insulin and glucose tolerance followup studies. Proc Am Assoc Canc Res 1957; 2: 228-229.
76. Lupulescu A. The role of vitamins A, beta-carotene, E and C in cancer cell biology. Int J Vit Nutr Res 1994; 63: 3-14.
77. Lamson DW, Brignall MS. Antioxidants in cancer therapy; their actions and interactions with oncologic therapies. Altem Med Rev 1999; 4: 304-329.
78. Howe GR, Hirohata T, Hislop TG, Iscovich JM, Yuan JM, Katsouyanni K, et al. Dietary factors and risk of breast cancer: combined analysis of 12 case-control studies. J Natl Cancer Inst 1990; 82: 561-569.
79. Lockwood K, Moesgaard SK, Folkers K. Partial and complete regression of breast cancer in patients in relation to dosage of coenzyme Q10. Biochem Biophys Res Commun 1994; 199: 1504-1508.
80. Langsjoen PH, Folkers K, Lyson K, Muratsu K, Lyson T, Langsjoen P. Pronounced increase of survival of patients with cardiomyopathy when treated with coenzyme Q10 and conventional therapy. Int J Tissue React 1990; 12: 163-168.
81. Langsjoen PH, Langsjoen AM. Overview of the use of CoQ10 in cardiovascular disease. BioFactors 1999; 9: 273-284. (www.csi.unian.it/coenzymeQ/overview.html).
82. Folkers K, Langsjoen P, Langsjoen PH. Therapy with coenzyme Q10 of patients in heart failure who are eligible or ineligible for a transplant. Biochem Biophys Res Commun 1992; 182: 247-253.
83. Bliznakov EG, Hunt GL. The Miracle Nutrient Coenzyme Q10. New York, NY, USA: Bantam 1986; 2.
84. Folkers K, Langsjoen P, Willis R, Richardson P, Xia L-J, Ye C-Q, Tamagawa H. Lovastatin decreases coenzyme Q levels in humans. Proc Natl Acad Sci USA 1990; 87: 8931-8934.
85. Groopman L. Contagion. The New Yorker, Medical Dispatch 1999 Sept 13: 34-49.
86. Hubbell LJ. New Pap Technology. The Seattle Times, Health & Medicine 1998; 30: D1.
87. Orr JW, Wilson K, Bodiford C, Cornwell A, Soong SJ, Honea KL, et al. Nutritional status of patients with untreated cervical cancer. II. Vitamin assessment. Am J Obstet Gynecol 1985; 151: 632-635.
88. Romney SL, Duttagupta C, Basu J, Palan P, Karp S, Slagle S, et al. Plasma vitamin C and uterine cervical dysplasia. Am J Obstet Gynecol 1985; 151: 976-980.
89. Singh NV, Gaby SK. Premalignant lesions: role of antioxidant vitamins and beta-carotene in risk reduction and prevention of malignant transformation. Am J Clin Nutr 1991; 53(1 Suppl): 386S-390S.
90. Cheraskin E, Ringsdorf WM, Hutchins K, Setyaadmadja A, Wideman GL. Carbohydrate metabolism and cervical (uterine) carcinoma. Am J Obst Gyn 1967; 97: 817-820.
91. Cheraskin E, Ringsdorf WM Jr, Hutchins K, Setyaadmadja A, Wideman GL. Effect of diet upon radiation response in cervical carcinoma of the uterus. Acta Cyto 1968; 12: 433-438.
92. Nathens AB, Neff MJ, Jurkovich GJ, Klotz P, Farver K, Ruzinski JT, et al. Randomized, prospective trial of antioxidant supplementation in critically ill surgical patients. Ann Surg 2002; 236: 814-822.
93. Bourne GH. The effect of vitamin C on the healing of wounds. Proc Nutr Soc 1946; 4: 204-211.
94. Lund CC, Crandon JH. Human experimental scurvy and the relation of vitamin C deficiency to post-operative pneumonia and to wound healing. JAMA 1941; 116: 663-668.
95. Bliznakov EG. Effect of stimulation of the host defense system by coenzyme Q10 on dibenzpyrene-induced tumors and infection with Friend leukemia virus in mice. Proc Natl Acad Sci USA 1970; 70: 390-394.
96. Peterson P, Gray Dawn. How the Coming Age Wave Will Transform America and the World. New York: Times Books, 1999; 256.
97. Pauling LJ. Case Report: Lysine/ascorbate-related amelioration of angina pectoris. J Orthomolecular Med 1991; 6: 144-146.
98. Fudenberg HH. Heterogeneity of Alzheimer's disease. Mol Neurobiol 1994; 9: 55-71.
99. Balin BJ, Gerard HC, Arking EJ, Appelt DM, Branigan PJ, Abrams JT, et al. Identification and localization of Chlamydia pneumoniae in the Alzheimer's brain. Med Microbiol Immunol (Berl) 1998; 187: 23-42.
100. Ely JTA, Fudenberg HH, Muirhead RJ, LaMarche MG, Krone CA, Buscher D, Stern EA. Urine mercury in micromercurialism: bimodal distribution and diagnostic implications. Bull Environ Contam Toxicol 1999; 63: 553-559.
101. Ely JTA. Risk factors for parenteral intoxication by mercury from dental amalgam. Bull Environ Contam Toxicol 2001; 67: 309-316.
102. Ely JTA. Mercury induced Alzheimer's disease: accelerating incidence? Bull Environ Contam Toxicol 2001; 67: 800-806.
103. Brune D, Gjerdet N, Paulsen G. Gastrointestinal and in vitro release of copper, cadmium, indium, mercury and zinc from conventional and copper-rich amalgams. Scand J Dent Res 1983; 91: 66-71.
104. Pleva J. Dental mercury-a public health hazard. Rev Environ Health 1994; 10: 1-27.
105. Thompson CM, Markesbery WR, Ehmann WD, Mao XY, Vance DE. Regional brain trace-element studies in Alzheimer's disease. Neurotoxicology 1988; 9: 1-7.
106. Pendergrass JC, Haley BE. Inhibition of brain tubulin-GTP interactions by mercury: Similarity to observations in Alzheimer's diseased brains. In: Sigel A, Sigel H, eds. Metal Ions in Biological Systems. Vol. 34. New York, NY, USA: Marcel Dekker; 1997; 461-478.
107. Cornett CR, Markesbery WR, Ehmann WD. Imbalances of trace elements related to oxidative damage in Alzheimer's disease brain. Neurotoxicology. 1998; 19: 339-345.
108. Wedeen RP. Lead, mercury and cadmium nephropathy. NeuroToxicol 1983; 4: 134-146.
109. Sunderman FW. Perils of mercury. Ann Clin Lab Sci 1988; 18: 89-101.
110. Ely JTA, Krone CA. Aging: predictions of a new perspective on old data. Exp Biol Med 2002; 227: 939-942.
111. Ou B, Huang D, Hampsch-Woodill M, Flanagan JA, Deemer EK. Analysis of antioxidant activities of common vegetables employing oxygen radical absorbance capacity (ORAC) and ferric reducing antioxidant power (FRAP) assays: a comparative study. J Agric Food Chem 2002; 50: 3122-3128.
112. Cao G, Booth SL, Sadowski JA, Prior RL. Increases in human plasma antioxidant capacity after consumption of controlled diets high in fruit and vegetables. Am J Clin Nutr 1998; 68(5): 1081-1087.